Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study

• Main Authors: Akihiko Asahina (Author), Yukari Okubo (Author), Akimichi Morita (Author), Yayoi Tada (Author), Atsuyuki Igarashi (Author), Richard G. Langley (Author), Delphine Deherder (Author), Mizuho Matano (Author), Veerle Vanvoorden (Author), Maggie Wang (Author), Mamitaro Ohtsuki (Author), Hidemi Nakagawa (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Introduction Bimekizumab treatment resulted in improved clinical outcomes in patients with moderate-to-severe plaque psoriasis in BE VIVID, a 52-week, phase 3, randomized, ustekinumab and placebo-controlled study. We present data from the BE VIVID Japan patient subpopulation. Methods Global...